JAPANESE PROSPECTIVE REAL WORLD REGISTRY OF CABOZANTINIB PLUS NIVOLUMABIN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA - JACUMET study
An Observational Study to Evaluate the Safety and Efficacy of Lenvatinib in HCC Subjects Who Have Progressive Disease After First Line Treatment With Checkpoint Inhibitors
The objective of this study is to evaluate the efficacy of lenvatinib in HCC subjects who have progressive disease after first line treatment with checkpoint inhibitors.
Approximately 20 subjects will be enrollment to evaluate the efficacy and safety of lenvatinib.
CT/MRI assessments will be made at end of first line treatment with checkpoint inhibitors, and every 8-12 weeks thereafter. Disease status will be determined at the site (ie. Investigator and/or radiologist) using RECIST version 1.1.
The primary efficacy endpoint is response rate (RR) defined as proportion of subjects with SD/PR/CR per RECIST 1.1.
An Open Label Phase II Study on the efficacy of Nivolumab(ONO-4538) in Japanese Subjects with cancer of unknown primary (CUP) (NivoCUP) - An Open Label Phase II Study on the efficacy of Nivolumab in Japanese Subjects with cancer of unknown primary (CUP) (NivoCUP)
100 项与 Kindai University Faculty of Medicine 相关的临床结果
0 项与 Kindai University Faculty of Medicine 相关的专利(医药)
100 项与 Kindai University Faculty of Medicine 相关的药物交易
100 项与 Kindai University Faculty of Medicine 相关的转化医学